GALECTIN THERAPEUTICS INC. - COMMON STOCK

Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023

26 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023

11 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023

07 Sep 2023 11:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update

14 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update

15 May 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023

27 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics’ Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases

18 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update

30 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

16 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

02 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

24 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

05 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders

29 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit

28 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update

14 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD

01 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Galectin Therapeutics to Present in Upcoming Conferences

14 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer

12 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

06 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022

08 Sep 2022 07:00:01 By Nasdaq GlobeNewswire